Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers

PURPOSE: KRAS-activating mutations are the most common oncogenic driver in non-small cell lung cancer (NSCLC), but efforts to directly target mutant KRAS have proved a formidable challenge. Therefore, multi-targeted therapy may offer a plausible strategy to effectively treat KRAS-driven NSCLCs. Here...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Hai, Josephine, Liu, Shengwu, Bufe, Lauren, Do, Khanh, Chen, Ting, Wang, Xiaoen, Ng, Christine, Li, Shuai, Tsao, Ming-Sound, Shapiro, Geoffrey I., Wong, Kwok-Kin
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690829/
https://ncbi.nlm.nih.gov/pubmed/28821559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1098
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi